Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
|Articles|March 19, 2019
- Psychiatric Times Vol 36, Issue 3
- Volume 36
- Issue 3
Overheard Conversation, ICU
Author(s)Richard M. Berlin, MD
Do I have to speak? I know you know...
Advertisement
–from a Line by Roberto Bolaño
I am dying with many things to say.
Do I have to speak? I know you know
My love was like mist thrown from the waves.
When I die, you will have many things to say.
Once more, my love, I will not obey.
March can be hushed and covered with snow.
I am dying with many things to say.
Do I have to speak? You know what you know
Articles in this issue
about 6 years ago
An Invitation: Psychiatric Malpractice Grand Roundsover 7 years ago
THE QUIZ: Chronic Pain and Traumatic Brain Injuriesover 7 years ago
Climate Disruption and the Psychiatric Patientover 7 years ago
Looking at the Past and Forward to the Futureover 7 years ago
The Movie on Your Patient’s Mindover 7 years ago
The Complexities Behind the Act of SuicideAdvertisement
Related to this article
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Spot SVT or POTS masquerading as panic attacks—key heart-rate clues, home maneuvers, and why anxiety can persist even after arrhythmia treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5